AstraZeneca’s Sone-Ve demonstrated improved survival in advanced CLDN18.2-positive gastric, esophageal and gastroesophageal junction cancer in the phase 3 CLARITY-Gastric01 study.
In the third line of treatment or later, the risk of death was reduced by 53 percent and median survival doubled to 10 months. In the overall study population, the risk of death was reduced by 42 percent. However, progression-free survival did not reach statistical significance.
Serious treatment-related adverse events of grade 3 or higher occurred in 36.4 percent of patients receiving Sone-Ve, compared with 44.8 percent in the control group. No new safety signals were identified.
Sone-Ve is also being evaluated in phase 3 as a first-line treatment and in phase 2 for other solid tumors.
